What is Trombonat 50?

Trombonat 50 is a 50 mg tablet containing eltrombopag olamine. Eltrombopag is an orally active small-molecule thrombopoietin receptor agonist. It acts on the thrombopoietin receptor, also known as c-Mpl, and activates signaling pathways that encourage the growth and development of certain bone-marrow cells involved in platelet production.

The medicine is primarily associated with the management of certain forms of thrombocytopenia, a condition in which the blood contains fewer platelets than normal. Depending on the approved indication, eltrombopag may be used in patients with conditions such as persistent or chronic immune thrombocytopenia (ITP) and certain forms of severe aplastic anemia. It has also been used in specific settings involving hepatitis C-associated thrombocytopenia under applicable treatment protocols.

Trombonat 50 is therefore not a general-purpose medicine for bleeding. The underlying cause of a low platelet count must be evaluated by a healthcare professional before treatment is considered.

Trombonat 50 Uses

The Trombonat 50 uses are related to conditions in which increasing platelet production may provide a clinical benefit.

Depending on the indication and applicable prescribing information, eltrombopag may be prescribed for:

• Management of persistent or chronic immune thrombocytopenia (ITP) in appropriate patients who have not responded adequately to previous treatments.
• Management of thrombocytopenia associated with certain treatment settings for chronic hepatitis C, where approved.
• Treatment of certain patients with severe aplastic anemia, including specific treatment protocols where eltrombopag is indicated.
• Supporting platelet production when a low platelet count is clinically significant and treatment with a thrombopoietin receptor agonist is considered appropriate.

The exact indication should always be confirmed from the patient’s prescription and the locally approved product information.

This medicine should only be used under the supervision of a qualified healthcare professional.

Trombonat 50 Benefits

The potential Trombonat 50 benefits are related to its ability to stimulate platelet production rather than directly treating every underlying cause of thrombocytopenia.

Potential clinical benefits include:

• Supports the body’s production of platelets.
• May help increase platelet counts in appropriate patients.
• Can form part of the management of certain chronic immune thrombocytopenia cases.
• May provide a treatment option for selected patients with severe aplastic anemia.
• May help healthcare professionals manage clinically significant thrombocytopenia as part of a broader treatment plan.
• Can reduce dependence on some platelet-supportive approaches in selected patients when clinically appropriate.

Eltrombopag does not provide a guaranteed cure for the underlying disease. Treatment response differs between individuals and depends on the cause and severity of thrombocytopenia and other medical factors.

How Does Trombonat 50 Work?

The active ingredient in Trombonat 50 is eltrombopag olamine. Eltrombopag is a thrombopoietin receptor agonist.

Thrombopoietin is a naturally occurring substance involved in the regulation of platelet production. Eltrombopag interacts with the transmembrane region of the human thrombopoietin receptor. This activates signaling pathways that promote the proliferation and differentiation of bone-marrow progenitor cells involved in platelet production.

In simple terms, the medicine helps stimulate the body’s platelet-producing system. As platelet production increases, platelet counts may rise in patients who respond to treatment.

Because platelet levels can become too high or remain below the desired range, treatment requires appropriate medical monitoring. The goal is not simply to produce as many platelets as possible but to achieve an appropriate clinical response while minimizing risks.

Trombonat 50 Dosage and Administration

The appropriate Trombonat 50 dosage is individualized by the prescribing healthcare professional. It can vary according to the medical condition being treated, age, liver function, previous treatment, platelet response, and other patient-specific factors.

Patients should follow the prescription and product information supplied by their healthcare professional. The dose should not be increased, reduced, stopped, or restarted independently.

Eltrombopag has clinically important food and mineral-interaction considerations. Certain products containing polyvalent cations, including calcium, magnesium, aluminum, iron, and zinc, can affect eltrombopag absorption. Therefore, the prescribing instructions concerning food, antacids, mineral supplements, and other medicines should be followed carefully.

Trombonat 50 Side Effects

Like all medicines, Trombonat 50 may cause side effects, although not everyone experiences them.

Common Side Effects

Reported adverse effects associated with eltrombopag can include:

• Nausea
• Diarrhea
• Headache
• Fatigue
• Cough
• Fever
• Upper respiratory tract infections
• Increased liver enzymes
• Muscle aches

The frequency and severity of adverse effects can differ according to the condition being treated, age, other medicines, and individual health factors.

Serious Side Effects

Eltrombopag can cause important complications that require medical attention. These include:

• Liver injury or hepatotoxicity
• Significant abnormalities in liver-function tests
• Blood clots or thromboembolic complications
• Portal vein thrombosis, particularly in certain patients with chronic liver disease
• Excessively high platelet counts
• Serious complications associated with underlying liver or blood disorders

Liver function and platelet counts may therefore need to be monitored during treatment.

If side effects persist or become severe, contact your healthcare provider promptly.

Warnings and Precautions

Trombonat 50 requires careful medical supervision because eltrombopag can affect liver function and platelet levels.

Liver Disease

Patients with existing liver problems may require special consideration. Eltrombopag can cause hepatotoxicity, and liver-function monitoring is an important part of appropriate treatment.

Risk of Blood Clots

Increasing platelet production can potentially contribute to thrombotic or thromboembolic complications. Patients with particular risk factors require careful assessment and monitoring.

Kidney Disease

People with impaired kidney function should inform their healthcare professional before treatment so that their overall medical status can be appropriately considered.

Pregnancy

Pregnancy should be discussed with a healthcare professional before treatment. The potential benefits and risks need to be assessed individually.

Breastfeeding

The prescribing information should be consulted regarding breastfeeding because recommendations can vary according to the treatment situation and current regulatory guidance.

Older Adults

Older patients may have additional medical conditions or take several medicines simultaneously. Their overall health and medication profile should be reviewed by a healthcare professional.

Allergies

Anyone with a known allergy or previous serious reaction to eltrombopag or any component of the formulation should inform their healthcare provider.

Driving and Mental Alertness

Patients experiencing symptoms such as dizziness, fatigue, or other effects that affect alertness should discuss these symptoms with their healthcare professional before driving or performing activities requiring full concentration.

Drug Interactions

Eltrombopag can interact with other medicines and supplements. Some substances containing polyvalent cations can reduce its absorption. Examples include certain antacids, mineral supplements, and products containing calcium, iron, magnesium, or zinc.

Patients should tell their healthcare professional about:

• Prescription medicines
• Over-the-counter medicines
• Antacids
• Vitamins
• Mineral supplements
• Herbal or traditional medicines
• Other treatments for blood or liver disorders

A complete medication history helps the healthcare professional identify potentially important interactions.

Monitoring During Treatment

Because eltrombopag affects platelet production and may affect the liver, treatment commonly involves clinical and laboratory monitoring.

Healthcare professionals may monitor:

• Platelet counts
• Liver-function tests
• Other blood-test parameters where clinically appropriate
• Signs or symptoms suggesting abnormal clotting
• Overall response to treatment

The frequency and type of monitoring depend on the indication and the patient’s individual circumstances.

Trombonat 50 Manufacturer

The package shown identifies Natco as the manufacturer. Trombonat 50 is presented as a 50 mg eltrombopag olamine tablet in a pack marked as 4 × 7 tablets.

Product packaging, availability, labeling, and approved indications can differ between markets. The information printed on the supplied pack and the applicable local prescribing information should therefore be checked before use.

Trombonat 50 Price

The Trombonat 50 price may vary depending on the pharmacy, location, pack size, applicable taxes, distributor, and market conditions. Because medicine prices can change, the current price should be confirmed with a licensed pharmacy or authorized healthcare supplier.

Price should not be the only consideration when selecting a prescription medicine. Patients should verify the product, strength, packaging, expiry date, and prescription requirements with a qualified healthcare professional or pharmacist.

Storage Instructions

General medicine-storage precautions include:

• Keep the tablets in their original packaging unless advised otherwise.
• Protect the medicine from excessive heat, moisture, and direct sunlight.
• Store according to the temperature and storage instructions stated on the product packaging.
• Keep the medicine out of reach of children.
• Do not use tablets after their expiry date.
• Do not use tablets if the packaging is damaged or the product appears abnormal.

For exact storage requirements, follow the manufacturer’s package information.

Frequently Asked Questions

1. What is Trombonat 50 used for?

Trombonat 50 contains eltrombopag olamine, a thrombopoietin receptor agonist. It may be prescribed for certain conditions associated with low platelet counts, including appropriate cases of immune thrombocytopenia and severe aplastic anemia. Approved indications can differ by country and patient population, so the medicine should be used only for the condition diagnosed by a healthcare professional.

2. How does Trombonat 50 work?

Eltrombopag stimulates the thrombopoietin receptor, activating biological signaling pathways involved in platelet production in the bone marrow. This can increase platelet production in patients who respond to treatment. It does not directly cure every underlying cause of thrombocytopenia.

3. Is Trombonat 50 safe?

Trombonat 50 can be an appropriate prescription treatment for selected patients when used under medical supervision. However, it can cause important adverse effects, including liver injury and blood-clotting complications. Doctors consider the patient’s condition, medical history, laboratory results, and other medicines before and during treatment.

4. Can Trombonat 50 be used long term?

Some conditions treated with eltrombopag may require extended treatment. Whether long-term therapy is appropriate depends on the patient’s response, platelet levels, underlying disease, liver function, and overall clinical status. Long-term treatment should be continued only according to the treating healthcare professional’s plan.

5. What happens if a dose is missed?

Patients should follow the missed-dose instructions provided by their healthcare professional or the product information. They should not independently compensate for a missed dose by taking extra medicine. If there is uncertainty about what to do after a missed dose, a pharmacist or doctor should be contacted.

6. Can Trombonat 50 be stopped suddenly?

Eltrombopag should not be stopped or restarted without medical advice. Changes in treatment can affect platelet levels, and the appropriate approach depends on the underlying condition and the patient’s response. A healthcare professional can determine whether treatment should continue, change, or stop.

7. Can Trombonat 50 be taken with food?

Food can affect eltrombopag absorption, particularly meals or products containing significant amounts of calcium. Certain mineral-containing products can also interfere with absorption. Patients should follow the specific administration instructions supplied with their prescription rather than making independent changes to how the medicine is taken.

8. What are the common Trombonat 50 side effects?

Reported side effects associated with eltrombopag include nausea, diarrhea, headache, fatigue, cough, fever, respiratory infections, muscle aches, and increases in liver enzymes. Not everyone experiences side effects, and their severity can vary. Persistent, severe, or unusual symptoms should be discussed promptly with a healthcare professional.

9. Who should use caution with Trombonat 50?

Particular caution may be required in people with liver disease, a history or risk of blood clots, kidney problems, pregnancy, or other significant medical conditions. Patients should provide their doctor with a complete medical and medication history before treatment.

10. How should Trombonat 50 be stored?

Trombonat 50 should generally be stored according to the conditions printed on its packaging and kept protected from unsuitable heat, moisture, and direct sunlight. It should remain out of children’s reach and should not be used after its expiry date.

Important Disclaimer

This product description is provided for general educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Trombonat 50 is a prescription medicine and should not be self-medicated. The appropriate indication, treatment plan, monitoring requirements, and dose are determined by a qualified healthcare professional based on the individual patient’s medical condition.

Medical information and approved indications may differ between countries and may be updated over time. Always refer to the current product information supplied with the medicine and consult a doctor or pharmacist for advice specific to the patient.